A type I interferon footprint in pre-operative biopsies is an independent biomarker that in combination with CD8+ T cell quantification can improve the prediction of response to neoadjuvant treatment of rectal adenocarcinoma
暂无分享,去创建一个
U. Yrlid | E. Angenete | Fabian Byvald | Azar Rezapour | Daniel Rydbeck | Viktor Tasselius | Gustaf Danielsson
[1] U. Yrlid,et al. A Fraction of CD8+ T Cells from Colorectal Liver Metastases Preferentially Repopulate Autologous Patient-Derived Xenograft Tumors as Tissue-Resident Memory T Cells , 2022, Cancers.
[2] Zaiyi Liu,et al. Predicting Neoadjuvant Chemoradiotherapy Response in Locally Advanced Rectal Cancer Using Tumor-Infiltrating Lymphocytes Density , 2021, Journal of inflammation research.
[3] Qingling Zhang,et al. Tumor-Infiltrating Cytotoxic T Cells and Tumor-Associated Macrophages Correlate With the Outcomes of Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer , 2021, Frontiers in Oncology.
[4] Jian Zhang,et al. The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting , 2021, Frontiers in Immunology.
[5] T. Sjöblom,et al. A Comprehensive Evaluation of Associations Between Routinely Collected Staging Information and The Response to (Chemo)Radiotherapy in Rectal Cancer , 2020, Cancers.
[6] A. Mantovani,et al. Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade , 2020, Immunity.
[7] Ron Yan,et al. Immune Effects of γδ T Cells in Colorectal Cancer: A Review , 2020, Frontiers in Immunology.
[8] Seiichiro Yamamoto,et al. Tumor-Infiltrating Lymphocytes in Biopsy Specimens Obtained 7 Days after Starting Chemoradiotherapy for Rectal Cancer Are Predictors of the Response to Chemoradiotherapy , 2020, Oncology.
[9] J. Galon,et al. A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy , 2020, Clinical Cancer Research.
[10] L. Pantanowitz,et al. Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma , 2020, Modern Pathology.
[11] Ruoxu Dou,et al. Density and distribution of lymphocytes in pretherapeutic rectal cancer and response to neoadjuvant therapy , 2020, Gastroenterology report.
[12] J. Galon,et al. Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer , 2020, Journal for immunotherapy of cancer.
[13] A. Abbas,et al. Tumor Microenvironment Mediators CD8+- and FOXP3+-Labeled T Lymphocytes Are Prospective Prognosticators in Curatively Treated Rectal Cancer Patients , 2020, Journal of Gastrointestinal Cancer.
[14] J. Galon,et al. Immunoscore and its introduction in clinical practice. , 2020, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[15] H. Ueno,et al. Predictive immunohistochemical features for tumour response to chemoradiotherapy in rectal cancer , 2020, BJS open.
[16] T. Zheng,et al. STING: a master regulator in the cancer-immunity cycle , 2019, Molecular Cancer.
[17] S. Mori,et al. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer , 2019, The British journal of surgery.
[18] Kebin Liu,et al. Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes , 2019, Journal of Immunotherapy for Cancer.
[19] Y. Huang,et al. Local environment in biopsy better predict the pathological response to neoadjuvant chemoradiotherapy in rectal cancer , 2019, Bioscience reports.
[20] J. Galon,et al. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies , 2019, Nature Reviews Drug Discovery.
[21] J. Lee,et al. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients , 2018, Breast Cancer Research and Treatment.
[22] P. Sehgal,et al. Interferon-α-induced cytoplasmic MxA structures in hepatoma Huh7 and primary endothelial cells , 2018, Contemporary oncology.
[23] F. Marincola,et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.
[24] P. Golstein,et al. An early history of T cell-mediated cytotoxicity , 2018, Nature Reviews Immunology.
[25] D. Aust,et al. Neoadjuvant radiochemotherapy decreases the total amount of tumor infiltrating lymphocytes, but increases the number of CD8+/Granzyme B+ (GrzB) cytotoxic T-cells in rectal cancer , 2018, Oncoimmunology.
[26] R. Langer,et al. Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy , 2018, Virchows Archiv.
[27] N. Baxter,et al. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. , 2017, The lancet. Gastroenterology & hepatology.
[28] Tracey F Lee-Pullen,et al. Tumour-infiltrating regulatory T cell density before neoadjuvant chemoradiotherapy for rectal cancer does not predict treatment response , 2017, Oncotarget.
[29] F. Qiu,et al. Tumor-infiltrating CD39+ γδTregs are novel immunosuppressive T cells in human colorectal cancer , 2017, Oncoimmunology.
[30] T. Gajewski,et al. The host STING pathway at the interface of cancer and immunity. , 2016, The Journal of clinical investigation.
[31] Xiao-yan Liu,et al. Analysis of tumor-infiltrating gamma delta T cells in rectal cancer. , 2016, World journal of gastroenterology.
[32] P. Staeheli,et al. Leukocyte-Derived IFN-α/β and Epithelial IFN-λ Constitute a Compartmentalized Mucosal Defense System that Restricts Enteric Virus Infections , 2015, PLoS pathogens.
[33] R. Weichselbaum,et al. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors. , 2014, Immunity.
[34] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[35] H. Nagawa,et al. Density of CD4(+) and CD8(+) T lymphocytes in biopsy samples can be a predictor of pathological response to chemoradiotherapy (CRT) for rectal cancer , 2011, Radiation oncology.
[36] Zlatko Trajanoski,et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] G. Kochs,et al. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. , 2011, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[38] J. Casanova,et al. Induction of MxA Gene Expression by Influenza A Virus Requires Type I or Type III Interferon Signaling , 2007, Journal of Virology.
[39] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[40] R. Wilkinson,et al. Plasmacytoid dendritic cells infiltrate the skin in positive tuberculin skin test indurations. , 2012, The Journal of investigative dermatology.
[41] Carsten Denkert,et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.